Best of ASCO - 2014 Annual Meeting

 

Welcome

Other

Developmental Therapeutics—Immunotherapy

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.

Branimir I. Sikic

3002

A phase 1/2 study with birinapant in combination with pembrolizumab.

Russell J. Schilder

TPS3131

A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.

James F. Spicer

3094

A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1).

Jason M. Redman

TPS3130

Anti-tumor immune responses in metastatic breast cancer exceptional responder patients.

Alusha A Mamchak

e15161

Association of anti-PD-1 (PD1) induced pneumonitis with persistent imaging and lung function abnormalities in some patients.

Douglas Buckner Johnson

e15147

Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response.

Jerome Galon

e15149

Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development.

Livija Deban

e15148

Immunotherapy awareness in the oncology patient population: An Irish hospital experience.

Umair Aleem

e15160

Impact of anti-infectious and corticosteroids on immunotherapy: Nivolumab and pembrozilumab follow-up in a French study.

Jean-Philippe Metges

e15157

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

Ryan J. Sullivan

3013

Multipeptide immunotherapy plus immunogenic chemotherapy in refractory cancer.

Juan Pablo Marquez-Manriquez

e15159

Oncologists rationale for testing PD-L1 expression levels in patients with disease states where PD-L1 testing is not part of the IO product specific indications.

Daniel F. Winkelman

e15164

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.

Monica M. Mita

3095

Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.

Joshua Ryan Richter

TPS3132

Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

Julie Marie Collins

3091

Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.

Daniel H. Johnson

TPS3133

Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.

Hani M. Babiker

e15150

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Morten Mau Soerensen

e15155

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.

Juneko E. Grilley-Olson

3093

Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.

Kerry Lynn Reynolds

3096

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.

Alan Anthoney

3092

The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities.

Daniel Wilhelm Mueller

TPS3129

Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies.

James B. Bussel

e15146

Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.

Maria Bassanelli

e15158